23andMe Therapeutics

23andMe is a genetics-led biopharmaceutical company that leverages its massive database of genotypic and phenotypic data from millions of customers to discover and develop novel therapies. Historically known for its direct-to-consumer genetic testing, the company established a therapeutics division to identify drug targets with human genetic validation. In late 2024, the company announced a major restructuring, discontinuing its internal drug development to focus on its core consumer business while seeking partners or buyers for its clinical-stage assets. Its lead programs include 23ME-00610, an antibody targeting CD200R1, and 23ME-01473, targeting ULBP6, both of which are in clinical trials for advanced solid tumors. Following a Chapter 11 filing in early 2025, the company's assets were acquired by the TTAM Research Institute, led by founder Anne Wojcicki, and the company transitioned to a private entity.